<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03196349</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00077510</org_study_id>
    <nct_id>NCT03196349</nct_id>
  </id_info>
  <brief_title>Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism</brief_title>
  <acronym>COVET</acronym>
  <official_title>Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism (COVET)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of Oral anticoagulants (warfarin, apixaban and rivaroxaban) for extended VEnous
      Thromboembolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Determine if apixaban is superior to warfarin in the reduction of clinically relevant
      bleeding. Determine if rivaroxaban is superior to warfarin in the reduction of clinically
      relevant bleeding. Determine if apixaban is non-inferior to warfarin in the prevention of
      recurrent venous thromboembolism. Determine if rivaroxaban is non-inferior to warfarin in the
      prevention of recurrent venous thromboembolism. An exploratory comparison of apixaban versus
      rivaroxaban for the prevention of clinically relevant bleeding and recurrent Venous
      Thromboembolism (VTEs) as a secondary objective.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2017</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically relevant bleeding event</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Primary safety event Clinically relevant bleeding (composite of major bleeding (MB) and/or clinically relevant non major bleeding (CRNMB))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrent Venous Thromboembolism (VTE)</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Primary efficacy outcome of recurrent VTE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>All cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Major bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically relevant non-major bleeding</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Clinically relevant non-major bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Premature termination of study medication</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>Premature termination of study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular events (myocardial infarction, ischemic stroke, peripheral arterial embolism)</measure>
    <time_frame>Randomization to 12 months</time_frame>
    <description>MI, ischemic stroke, peripheral arterial embolism</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">3165</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to Warfarin will have warfarin administered daily in order to maintain a target INR of 2-3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to Apixaban will have apixaban administered study drug of 2.5mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to Rivaroxaban will have rivaroxaban administered study drug of 20mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3</description>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban 2.5 MG</intervention_name>
    <description>Will be randomized to receive open label apixaban of 2.5 mg twice daily</description>
    <arm_group_label>Apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 20 MG</intervention_name>
    <description>Will be randomized to receive open label rivaroxaban of 20mg daily</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Have confirmed acute, symptomatic and unprovoked DVT/PE.

               -  Have completed an initial treatment course of oral anticoagulant therapy for 3-12
                  months.

               -  At high risk for recurrent venous thromboembolism after completion of the initial
                  treatment course.

               -  Have the capacity to understand and sign an informed consent form.

               -  Be 18 years of age and older.

               -  Under the direct care of a physician for treatment of VTE for the length of time
                  in the study.

        Exclusion Criteria:

          -  • creatinine clearance (CrCl) &lt; 30 mL/min as determined by Cockcroft-Gault formula

               -  significant liver disease (Child-Pugh B or C)

               -  concomitant use of medications that are strong P-glycoprotein or CYP3A4
                  inducers/inhibitors

               -  life expectancy &lt; 3 months

               -  Currently pregnant or breast feeding

               -  Active Cancer defined as:

               -  Diagnosed with cancer within the past 6 months; or

               -  Recurrent, regionally advanced or metastatic disease;

               -  Currently receiving treatment or have received any treatment for cancer during
                  the 6 months prior to randomization; or

               -  A hematologic malignancy not in complete remission

               -  Unwilling/ unlikely to agree to follow up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Ortel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gayle Passmore, MBA</last_name>
    <phone>919-886-8641</phone>
    <email>gayle.e.passmore@duke.edu</email>
  </overall_contact>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <last_update_submitted>June 20, 2017</last_update_submitted>
  <last_update_submitted_qc>June 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

